Suchergebnisse

Climate change and global population increase are two converging forces that will jointly challenge researchers to design programs that ensure crop production systems meet the world s food demand. Climate change will potentially reduce productivity while a global population increase will require more food. If productivity is not improved for future climatic conditions, food insecurity may foster major economic and political uncertainty. Given the importance of grain legumes in general common bean (Phaseolus vulgaris L.) in particular a workshop entitled Improving Tolerance of Common Bean to Abiotic Stresses was held with the goal of developing an interdisciplinary research agenda designed to take advantage of modern genotyping and breeding approaches that are coupled with large scale phenotyping efforts to improve common bean. Features of the program included a multinational phenotyping effort to evaluate the major common bean core germplasm collections and appropriate genetic populations. The phenotyping effort will emphasise the response of root and shoot traits to individual and combined stress conditions. These populations would also be genotyped using newly emerging high density single nucleotide polymorphism (SNP) marker arrays or next generation sequencing technology. Association analysis of the core collections aims to identify key loci associated with the response to the stress conditions. Companion bi-parental quantitative trait loci (QTL) experiments will act as confirmation experiments for the association analysis. The upcoming release of the genome sequence of common bean will be leveraged by utilising population genomic approaches to discover genomic regions that differentiate stress-responsive and non-responsive genotypes. The genome sequence will also enable global gene expression studies that will highlight specific molecular-based stress responses. This collective knowledge will inform the selection of parental lines to improve the efficiency of common bean improvement programs.

It is widely accepted that rigorous rehabilitation exercises after a stroke can help restore some functionality. However for many patients, this means exercises at home with minimal, if any, clinician support. Technologies that help motivate and promote good exercises offer significant potential but need to be designed to realistically take account of real homes and real lives of the people who have had a stroke. As part of the Motivating Mobility project, we carried out a series of visits to homes of people living with stroke and photographed their homes. In contrast to many utopian smart home scenarios, the elderly of today live in homes that were built as homes fit for heroes' but have been evolved and adapted over time and present significant challenges for the design of in‐home rehabilitation technologies. These challenges include the uses and repurposing of use of rooms, attitudes to and uses of existing technologies, space available in the home, feelings about different spaces within homes and individual preferences and interests. The findings provide a set of sensitivities that will help shape and frame ongoing design work for the successful deployment of rehabilitation technologies in real homes.

This book explores the intersections between leisure and health. It reveals and critiques the nuanced ways that leisure impacts health and considers how health professions use leisure as 'tool'. Case studies present developing leisure and health themes, in relation emerging environmental, health and societal challenges that confront the world.

This is the author accepted manuscript. ; The Common European Asylum System aims to establish common standards for refugee status determination among EU member states. Combining insights from legal and political geography we bring the depth and scale of this challenge into sharp relief. Drawing on a detailed ethnography of asylum adjudication involving over 850 in person asylum appeal observations, we point towards practical differences in the spatio-temporality, materiality and logistics of asylum appeal processes as they are operationalised in seven European countries. Our analysis achieves three things. Firstly we identify a key zone of differences at the level of concrete, everyday implementation that has largely escaped academic attention, which allows us to critically assess the notion of harmonization of asylum policies in new ways. 3 Secondly, drawing on legal- and political-geographical concepts, we offer a way to conceptualise this zone by paying attention to the spatio-temporality, materiality and logistics it involves. Thirdly, we offer critical legal logistics as a new direction for scholarship in legal geography and beyond that promises to prise open the previously obscured mechanics of contemporary legal systems. ; Economic and Social Research Council (ESRC) ; European Research Council (ERC)

Background: Government- and charity-funded medical research and private sector research and development (R&D) are widely held to be complements. The only attempts to measure this complementarity so far have used data from the United States of America and are inevitably increasingly out of date. This study estimates the magnitude of the effect of government and charity biomedical and health research expenditure in the United Kingdom (UK), separately and in total, on subsequent private pharmaceutical sector R&D expenditure in the UK. Methods: The results for this study are obtained by fitting an econometric vector error correction model (VECM) to time series for biomedical and health R&D expenditure in the UK for ten disease areas (including 'other') for the government, charity and private sectors. The VECM model describes the relationship between public (i.e. government and charities combined) sector expenditure, private sector expenditure and global pharmaceutical sales as a combination of a long-term equilibrium and short-term movements. Results: There is a statistically significant complementary relationship between public biomedical and health research expenditure and private pharmaceutical R&D expenditure. A 1 % increase in public sector expenditure is associated in the best-fit model with a 0.81 % increase in private sector expenditure. Sensitivity analysis produces a similar and statistically significant result with a slightly smaller positive elasticity of 0.68. Overall, every additional £1 of public research expenditure is associated with an additional £0.83-£1.07 of private sector R&D spend in the UK; 44 % of that additional private sector expenditure occurs within 1 year, with the remainder accumulating over decades. This spillover effect implies a real annual rate of return (in terms of economic impact) to public biomedical and health research in the UK of 15-18 %. When combined with previous estimates of the health gain that results from public medical research in cancer and cardiovascular disease, the total rate of return would be around 24-28 %. Conclusion: Overall, this suggests that government and charity funded research in the UK crowds in additional private sector R&D in the UK. The implied historical returns from UK government and charity funded investment in medical research in the UK compare favourably with the rates of return achieved on investments in the rest of the UK economy and are greatly in excess of the 3.5 % real annual rate of return required by the UK government to public investments generally.

Background: Government- and charity-funded medical research and private sector research and development (R&D) are widely held to be complements. The only attempts to measure this complementarity so far have used data from the United States of America and are inevitably increasingly out of date. This study estimates the magnitude of the effect of government and charity biomedical and health research expenditure in the United Kingdom (UK), separately and in total, on subsequent private pharmaceutical sector R&D expenditure in the UK. Methods: The results for this study are obtained by fitting an econometric vector error correction model (VECM) to time series for biomedical and health R&D expenditure in the UK for ten disease areas (including 'other') for the government, charity and private sectors. The VECM model describes the relationship between public (i.e. government and charities combined) sector expenditure, private sector expenditure and global pharmaceutical sales as a combination of a long-term equilibrium and short-term movements. Results: There is a statistically significant complementary relationship between public biomedical and health research expenditure and private pharmaceutical R&D expenditure. A 1 % increase in public sector expenditure is associated in the best-fit model with a 0.81 % increase in private sector expenditure. Sensitivity analysis produces a similar and statistically significant result with a slightly smaller positive elasticity of 0.68. Overall, every additional £1 of public research expenditure is associated with an additional £0.83-£1.07 of private sector R&D spend in the UK; 44 % of that additional private sector expenditure occurs within 1 year, with the remainder accumulating over decades. This spillover effect implies a real annual rate of return (in terms of economic impact) to public biomedical and health research in the UK of 15-18 %. When combined with previous estimates of the health gain that results from public medical research in cancer and cardiovascular disease, the total rate of return would be around 24-28 %. Conclusion: Overall, this suggests that government and charity funded research in the UK crowds in additional private sector R&D in the UK. The implied historical returns from UK government and charity funded investment in medical research in the UK compare favourably with the rates of return achieved on investments in the rest of the UK economy and are greatly in excess of the 3.5 % real annual rate of return required by the UK government to public investments generally.

BACKGROUND: Government- and charity-funded medical research and private sector research and development (R&D) are widely held to be complements. The only attempts to measure this complementarity so far have used data from the United States of America and are inevitably increasingly out of date. This study estimates the magnitude of the effect of government and charity biomedical and health research expenditure in the United Kingdom (UK), separately and in total, on subsequent private pharmaceutical sector R&D expenditure in the UK. METHODS: The results for this study are obtained by fitting an econometric vector error correction model (VECM) to time series for biomedical and health R&D expenditure in the UK for ten disease areas (including 'other') for the government, charity and private sectors. The VECM model describes the relationship between public (i.e. government and charities combined) sector expenditure, private sector expenditure and global pharmaceutical sales as a combination of a long-term equilibrium and short-term movements. RESULTS: There is a statistically significant complementary relationship between public biomedical and health research expenditure and private pharmaceutical R&D expenditure. A 1% increase in public sector expenditure is associated in the best-fit model with a 0.81% increase in private sector expenditure. Sensitivity analysis produces a similar and statistically significant result with a slightly smaller positive elasticity of 0.68. Overall, every additional £1 of public research expenditure is associated with an additional £0.83-£1.07 of private sector R&D spend in the UK; 44% of that additional private sector expenditure occurs within 1 year, with the remainder accumulating over decades. This spillover effect implies a real annual rate of return (in terms of economic impact) to public biomedical and health research in the UK of 15-18%. When combined with previous estimates of the health gain that results from public medical research in cancer and cardiovascular disease, the total rate of return would be around 24-28%. CONCLUSION: Overall, this suggests that government and charity funded research in the UK crowds in additional private sector R&D in the UK. The implied historical returns from UK government and charity funded investment in medical research in the UK compare favourably with the rates of return achieved on investments in the rest of the UK economy and are greatly in excess of the 3.5% real annual rate of return required by the UK government to public investments generally.

Abstract Background Government- and charity-funded medical research and private sector research and development (R&D) are widely held to be complements. The only attempts to measure this complementarity so far have used data from the United States of America and are inevitably increasingly out of date. This study estimates the magnitude of the effect of government and charity biomedical and health research expenditure in the United Kingdom (UK), separately and in total, on subsequent private pharmaceutical sector R&D expenditure in the UK. Methods The results for this study are obtained by fitting an econometric vector error correction model (VECM) to time series for biomedical and health R&D expenditure in the UK for ten disease areas (including 'other') for the government, charity and private sectors. The VECM model describes the relationship between public (i.e. government and charities combined) sector expenditure, private sector expenditure and global pharmaceutical sales as a combination of a long-term equilibrium and short-term movements. Results There is a statistically significant complementary relationship between public biomedical and health research expenditure and private pharmaceutical R&D expenditure. A 1 % increase in public sector expenditure is associated in the best-fit model with a 0.81 % increase in private sector expenditure. Sensitivity analysis produces a similar and statistically significant result with a slightly smaller positive elasticity of 0.68. Overall, every additional £1 of public research expenditure is associated with an additional £0.83–£1.07 of private sector R&D spend in the UK; 44 % of that additional private sector expenditure occurs within 1 year, with the remainder accumulating over decades. This spillover effect implies a real annual rate of return (in terms of economic impact) to public biomedical and health research in the UK of 15–18 %. When combined with previous estimates of the health gain that results from public medical research in cancer and cardiovascular disease, the total rate of return would be around 24–28 %. Conclusion Overall, this suggests that government and charity funded research in the UK crowds in additional private sector R&D in the UK. The implied historical returns from UK government and charity funded investment .

ROCK'70. by Chris Hodenfield.PRAIRIE FARMER AND WLS: THE BURRIDGE D. BUTLER YEARS. by James F. Evans.MARY RENAULT. by Peter Wolfe.MELODRAMA UNVEILED, by David Grimstead.BALLADS, by M. J. C. Hodgart.JIM WHITEWOLF: THE LIFE OF A KIOWA APACHE. Edited with an Introduction and Epilogue by Charles S. Brant.OHIO, A PERSONAL PORTRAIT OF THE 17TH STATE, by Dick Perry and Bruce Goldflies.THE HALL OF FAME OF WESTERN FILM STARS, by Ernest N. Corneau.THE FILMS OF ORSON WELLES, by Charles Higham.THE BALLAD AS SONG. by Bertrand Harris Bronson.

The prevalence and attraction of dissident sectarian movements today raises anumber of significant questions about both their participants and their role incontemporary society. The present study examines one such group, the Spiritualistsof Mexico, who form not only a dissident religious movement butalso provide an important health care delivery system (Finkler 1980b, 1981a,1981c, 1983). While the Mexican example is the focus of our attention, the discussion has broader implications because movements of the Spiritualist type exist in many cultures (e.g., Berger 1969; Burridge.1969; LaBarre 1971; Lanternari 1963, 1974; Lewis 1971; Wilson 1963).

Abstract
The impacts on adult social work in England of the Covid-19 pandemic were sudden and are proving long-standing. In England, many social workers moved to home working and virtual contact with colleagues, managers, staff from other agencies and service users. A first national lockdown was followed by a lessening of restrictions, but a second wave started at the end of Summer 2020 and restrictions were re-introduced. This study draws on telephone interviews with a sample of twenty-two social workers working with adults in a wide range of roles and settings in ten local authorities and two National Health Service Hospital Trusts, interviewed August–October 2020. Following transcription, interview data were analysed thematically. Findings are reported under three emerging themes: using professional judgement, new and emerging case work and embedding change. These are compared with findings from studies of practice in children's services and of surveys of social workers during the Covid-19 pandemic. Implications for practice, service users and research are explored.